Market: NASD |
Currency: USD
Address: 1300 South El Camino Real
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
📈 Kronos Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Kronos Bio, Inc.
| Date | Reported EPS |
|---|
| 2025-08-07 | - |
| 2024-11-13 | -0.23 |
| 2024-08-08 | -0.27 |
| 2024-05-09 | -0.5 |
| 2024-03-21 | -0.43 |
| 2023-11-13 | -0.54 |
| 2023-08-08 | -0.52 |
| 2023-05-10 | -0.46 |
| 2023-03-15 | -0.56 |
| 2022-11-08 | -0.57 |
| 2022-08-04 | -0.59 |
| 2022-05-04 | -0.65 |
| 2022-02-24 | -1.13 |
| 2021-11-09 | -0.61 |
| 2021-08-12 | -0.53 |
| 2021-05-11 | -0.48 |
| 2021-03-23 | -0.7 |
| 2020-11-18 | -6.48 |
📰 Related News & Research
No related articles found for "kronos bio".
